Human IGFBP1 enzyme-linked immunoassay kit（one step）
| Specification | 96 Test |
|---|---|
| Sensitivity | 1.13 pg/ml (50 μl)；15.75 pg/ml (10 μl)； |
| Standard Curve Range | 13.72~10000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Detectable sample | serum, plasma |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 60min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0057 | 0.0053 | 0.0055 | |
| 13.72 | 0.0083 | 0.0082 | 0.0083 | 0.0028 |
| 41.15 | 0.0165 | 0.0154 | 0.0160 | 0.0105 |
| 123.46 | 0.0426 | 0.0463 | 0.0445 | 0.0390 |
| 370.37 | 0.1283 | 0.1181 | 0.1232 | 0.1177 |
| 1111.11 | 0.3838 | 0.3516 | 0.3677 | 0.3622 |
| 3333.33 | 1.0460 | 0.9522 | 0.9991 | 0.9936 |
| 10000.00 | 2.3570 | 2.2190 | 2.2880 | 2.2825 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 236.9 | 1109.1 | 3258.2 | 230.4 | 1101.7 | 3259.2 |
| Standard Deviation | 16.1 | 73.4 | 254.8 | 4.6 | 64.8 | 84.5 |
| Coefficient of Variation(%) | 6.8 | 6.5 | 7.8 | 2.8 | 3.0 | 3.0 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of Human IGFBP1 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 90% to 119% with an overall mean recovery of 105%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
|---|---|---|---|---|
| Serum | 30 | 0.72-26.08 | 100 | 8.56 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of Human IGFBP1 in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: IGFBP1
The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. ALS (Acid Labile Subunit) is a liver-derived protein that exists in a ternary complex with Insulin-like Growth Factor (IGF)-binding Protein-3 (IGFBP-3) or IGFBP-5, and either IGF-I or IGF-II. ALS increases the half-life of IGF/IGFBP complexes in circulation.
